QQ客服 官方微博 反馈留言

浏览/检索结果: 共12条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文 CANCER RESEARCH, 2018, 卷号: 78, 期号: 4 作者:  Domchek, Susan M.;  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文 CANCER RESEARCH, 2018, 卷号: 78, 期号: 4 作者:  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Masuda, Norikazu 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05 Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文 2018, 卷号: 78, 期号: 4 作者:  Domchek, Susan M.;  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/03 Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文 CANCER RESEARCH, 2018-02-01 作者:  Domchek, Susan M.;  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 期刊论文 2018, 卷号: 78, 期号: 13 作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan 收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03 OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 会议论文 CANCER RESEARCH, 2018-07-01 作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan 收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03 OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). 会议论文 作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan M. 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05 Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation 期刊论文 NEW ENGLAND JOURNAL OF MEDICINE, 2017, 卷号: 377, 期号: 6 作者:  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan M. 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05 OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 期刊论文 2017, 卷号: 35 作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan M. 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/04 OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). 期刊论文 2017, 卷号: 35, 期号: 18 作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan M. 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04